Paper Details

  1. Home
  2. Paper Details

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Author: , BaumM, BudzarA U, CuzickJ, ForbesJ, HoughtonJ H, KlijnJ G M, SahmoudT

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tamoxifen is an established treatment for postmenopausal women with hormone-sensitive breast cancer. This study aims to compare the safety and efficacy of tamoxifen with anastrozole alone and in combination.
Paper Details　
Original Abstract of the Article :
In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, it is associated with several side-effects including endometrial cancer and thromboembolic disorders. We aimed to compare the safety and efficacy outcomes of tamoxi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(02)09088-8

データ提供：米国国立医学図書館（NLM）

Anastrozole vs Tamoxifen for Breast Cancer Treatment

The desert of breast cancer research continues to be a journey of discovery. This study compares the efficacy and safety of anastrozole, a type of aromatase inhibitor, to tamoxifen, a selective estrogen receptor modulator, for treating postmenopausal women with hormone-sensitive early breast cancer. The study aimed to determine if anastrozole alone or in combination with tamoxifen was as effective as tamoxifen alone.

The study found that anastrozole, either alone or in combination with tamoxifen, was as effective as tamoxifen alone in preventing breast cancer recurrence. However, anastrozole was associated with fewer side effects, particularly endometrial cancer and thromboembolic disorders, making it a potentially safer treatment option.

A Safer Treatment Option for Breast Cancer

This research indicates that anastrozole could be a more favorable treatment option for postmenopausal women with hormone-sensitive early breast cancer. The drug's effectiveness combined with its lower risk of side effects makes it a promising alternative to tamoxifen.

Navigating Treatment Decisions

This study provides valuable insights for healthcare providers and patients when making treatment decisions for breast cancer. By understanding the risks and benefits of different treatment options, patients can make informed decisions about the best course of action for their individual circumstances.

Dr.Camel's Conclusion

This study adds another layer of knowledge to our understanding of breast cancer treatment. Anastrozole emerges as a potential oasis in the desert of treatment options, offering a safer and equally effective alternative to tamoxifen. This research reinforces the importance of ongoing research and exploration of new treatment options for breast cancer.

Date :
  1. Date Completed 2002-07-11
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

12090977

DOI: Digital Object Identifier

10.1016/s0140-6736(02)09088-8

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.